Baolam Ho
Family Medicine · Gaffney, SCNPI 1023632858
Payments from drug & device makers
Across 120 payments — averaging $31.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$467
- Novo Nordisk$347
- Pfizer$216
- Verona Pharma, Inc.$198
- Astellas Pharma US Inc$153
- plus $924 from 13 others
What the payments were for
- Food & beverage$3,751100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $1,446 |
| Amgen | 13 | $467 |
| Novo Nordisk | 22 | $347 |
| Pfizer | 10 | $216 |
| Verona Pharma, Inc. | 10 | $198 |
| Astellas Pharma US Inc | 4 | $153 |
| Phathom Pharmaceuticals, Inc. | 5 | $129 |
| Boehringer Ingelheim | 3 | $122 |
| AbbVie | 8 | $121 |
| Inari Medical, Inc. | 3 | $119 |
| Lilly USA, LLC | 3 | $114 |
| Exact Sciences | 6 | $90 |
| Dexcom, Inc. | 4 | $88 |
| Stryker | 1 | $31 |
| Eisai Inc. | 1 | $28 |
| Merck | 2 | $27 |
| Medtronic | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,751 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $49,688 |
| EliquisApixaban | 45 | $38,630 |
| FarxigaDapagliflozin Propanediol | 31 | $28,186 |
| JardianceEmpagliflozin | 25 | $19,720 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,189 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $12,787 |
| Repatha SureclickEvolocumab | 11 | $7,020 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,862 |
| Esomeprazole Magnesium | 24 | $1,142 |
| Celecoxib | 28 | $1,066 |
| Omeprazole | 60 | $1,000 |
| Atorvastatin Calcium | 96 | $993 |
| Gabapentin | 69 | $792 |
| Levothyroxine Sodium | 73 | $605 |
| Pantoprazole Sodium | 53 | $598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $347 | $49,68838 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,446 | $40,97244 claims |
| PfizerEliquis | $216 | $38,63045 claims |
| Boehringer IngelheimJardiance | $122 | $19,72025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Gaffney
- Richard CutchinGaffney$270K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.